Autonomous Growth of a Human Neuroblastoma Cell Line is Mediated by Insulin-like Growth Factor II

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1989 Sep 1

PMID 2547840

Citations 50

Authors

J A Romanus

L J Helman

M J Cooper

M M Rechler

M A Israel

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor II (IGF-II) mRNA was increased in two of eight neuroblastomas and in eight of eight pheochromocytomas, tumors of the adrenal medulla that occur in childhood and adulthood, respectively. RNA encoding the type I IGF receptor, the receptor thought to mediate the mitogenic effects of IGF-I and IGF-II, also was uniformly expressed in these cells. To assess the role of IGF-II in the growth of these tumor cells, we have used the SK-N-AS cultured neuroblastoma cell line, which can be continuously propagated in mitogen-free medium, as a model system. Our results strongly suggest that IGF-II, synthesized by SK-N-AS cells and acting through type I IGF receptors, contributes to the autonomous growth of this tumor cell line. (a) SK-N-AS cells synthesized large amounts of IGF-II RNA and secreted greater than 50 ng/ml of IGF-II (as determined by specific radioimmuno- and radioreceptor assays). Little, if any, IGF-I RNA or immunoreactive IGF-I were detected. (b) SK-N-AS cells possess type I IGF receptors. (c) Exogenous IGF-I and IGF-II stimulated DNA synthesis in SK-N-AS cells, and this stimulation was abolished by a blocking antibody to the type I IGF receptor. (d) This anti-receptor antibody also abolished the multiplication of SK-N-AS cells in the absence of added mitogens. We conclude that IGF-II is an autocrine growth factor for SK-N-AS cells and suggest that this mechanism may contribute to the growth of some adrenal medullary tumors.

Citing Articles

Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma.

Stauffer S, Roth J, Hernandez E, Kowalczyk J, Sealover N, Hebron K Cancers (Basel). 2024; 16(13).

PMID: 39001383 PMC: 11240493. DOI: 10.3390/cancers16132320.

MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.

Tesan Tomic T, Olausson J, Rehammar A, Deland L, Muth A, Ejeskar K PLoS Genet. 2020; 16(6):e1008803.

PMID: 32511227 PMC: 7329139. DOI: 10.1371/journal.pgen.1008803.

Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.

Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J Invest New Drugs. 2020; 38(6):1677-1686.

PMID: 32436058 DOI: 10.1007/s10637-020-00933-2.

The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.

Mazar J, Gordon C, Naga V, Westmoreland T Anticancer Agents Med Chem. 2020; 20(13):1613-1625.

PMID: 32329693 PMC: 7527568. DOI: 10.2174/1871520620666200424123834.

miR-483-3p promotes proliferation and migration of neuroblastoma cells by targeting PUMA.

Wu K, Wang J, He J, Chen Q, Yang L Int J Clin Exp Pathol. 2020; 11(2):490-501.

PMID: 31938135 PMC: 6958035.

References

Aviv H, Leder P . Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci U S A. 1972; 69(6):1408-12. PMC: 426713. DOI: 10.1073/pnas.69.6.1408. View

Nakanishi Y, Mulshine J, Kasprzyk P, Natale R, Maneckjee R, Avis I . Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988; 82(1):354-9. PMC: 303516. DOI: 10.1172/JCI113594. View

Chirgwin J, Przybyla A, MacDonald R, Rutter W . Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18(24):5294-9. DOI: 10.1021/bi00591a005. View

Moses A, NISSLEY S, SHORT P, Rechler M, White R, Knight A . Increased levels of multiplication-stimulating activity, an insulin-like growth factor, in fetal rat serum. Proc Natl Acad Sci U S A. 1980; 77(6):3649-53. PMC: 349675. DOI: 10.1073/pnas.77.6.3649. View

Rechler M, Romanus J, Knight A, NISSLEY S, HUMBEL R . Receptors for insulinlike growth factor I are defective in fibroblasts cultured from a patient with leprechaunism. J Clin Invest. 1981; 68(5):1356-65. PMC: 370932. DOI: 10.1172/jci110383. View

Fu X, Su C, Lee Y, HINTZ R, BIEMPICA L, Snyder R . Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol. 1988; 62(9):3422-30. PMC: 253466. DOI: 10.1128/JVI.62.9.3422-3430.1988. View

Hoppener J, Mosselman S, Roholl P, Lambrechts C, Slebos R, Lips C . Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J. 1988; 7(5):1379-85. PMC: 458387. DOI: 10.1002/j.1460-2075.1988.tb02954.x. View

Jansen M, van der Kammen R, van Schaik F, Sussenbach J . Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. Biochim Biophys Acta. 1988; 950(3):282-95. DOI: 10.1016/0167-4781(88)90124-8. View

Ueno T, Takahashi K, Matsuguchi T, Ikejiri K, Endo H, Yamamoto M . Reactivation of rat insulin-like growth factor II gene during hepatocarcinogenesis. Carcinogenesis. 1988; 9(10):1779-83. DOI: 10.1093/carcin/9.10.1779. View

10.

Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A . Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res. 1988; 48(23):6691-6. View

11.

Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D . Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988; 48(23):6844-9. View

12.

Nakanishi Y, Cuttitta F, Kasprzyk P, Avis I, Steinberg S, Gazdar A . Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth?. Exp Cell Biol. 1988; 56(1-2):74-85. DOI: 10.1159/000163465. View

13.

Maciel R, Moses A, Villone G, Tramontano D, Ingbar S . Demonstration of the production and physiological role of insulin-like growth factor II in rat thyroid follicular cells in culture. J Clin Invest. 1988; 82(5):1546-53. PMC: 442721. DOI: 10.1172/JCI113764. View

14.

Daughaday W, Emanuele M, Brooks M, Barbato A, Kapadia M, Rotwein P . Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988; 319(22):1434-40. DOI: 10.1056/NEJM198812013192202. View

15.

Kiess W, Thomas C, Greenstein L, Lee L, Sklar M, Rechler M . Insulin-like growth factor-II (IGF-II) inhibits both the cellular uptake of beta-galactosidase and the binding of beta-galactosidase to purified IGF-II/mannose 6-phosphate receptor. J Biol Chem. 1989; 264(8):4710-4. View

16.

Yee D, Paik S, Lebovic G, Marcus R, Favoni R, Cullen K . Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989; 3(3):509-17. DOI: 10.1210/mend-3-3-509. View

17.

Furlanetto R, DiCarlo J, Wisehart C . The type II insulin-like growth factor receptor does not mediate deoxyribonucleic acid synthesis in human fibroblasts. J Clin Endocrinol Metab. 1987; 64(6):1142-9. DOI: 10.1210/jcem-64-6-1142. View

18.

Soares M, Turken A, Ishii D, Mills L, Episkopou V, Cotter S . Rat insulin-like growth factor II gene. A single gene with two promoters expressing a multitranscript family. J Mol Biol. 1986; 192(4):737-52. DOI: 10.1016/0022-2836(86)90025-2. View

19.

Gowan L, Hampton B, Hill D, SCHLUETER R, Perdue J . Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. Endocrinology. 1987; 121(2):449-58. DOI: 10.1210/endo-121-2-449. View

20.

Kiess W, Haskell J, Lee L, Greenstein L, Miller B, Aarons A . An antibody that blocks insulin-like growth factor (IGF) binding to the type II IGF receptor is neither an agonist nor an inhibitor of IGF-stimulated biologic responses in L6 myoblasts. J Biol Chem. 1987; 262(26):12745-51. View